Zobrazeno 1 - 10
of 44
pro vyhledávání: ''
Autor:
Jingfei Ma, Asif Rashid, Subramanya Sandesh, Anuj Verma, Jia Sun, Ignacio I. Wistuba, Jason Stafford, Aliya Qayyum, Ken Pin Hwang, Rony Avritscher, Richard L. Ehman, Ahmed Kaseb, Manal M. Hassan, Roberto Carmagnani Pestana, Hesham M. Amin, Dipen M. Maru
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-6 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Currently, there are no imaging predictors of immunotherapy outcome in hepatocellular carcinoma (HCC). The study aim was to determine if stiffness changes measured by magnetic resonance elastography (MRE) can be a predictor of immunotherap
Autor:
Marieke J. Krimphove, Luis A. Kluth, David F. Friedlander, Praful Ravi, Adam S. Kibel, Toni K. Choueiri, Patrick A. Ott, Karl H. Tully, Quoc-Dien Trinh, Maya Marchese, Stuart R. Lipsitz, Kerry L. Kilbridge
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background The introduction of immune checkpoint inhibitors has led to a survival benefit in patients with advanced melanoma; however data on the adoption of immunotherapy in the community are scarce. Methods Using the National Cancer Database, we id
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Immune-checkpoint inhibitors (ICIs) emerged as a novel class of drugs for the treatment of a broad spectrum of malignancies. ICIs can produce durable antitumor responses but they are also associated with immune-related adverse events (irAE
Autor:
Jii Bum Lee, Seung Hoon Beom, Minkyu Jung, Sun Young Rha, Jun Yong Park, Woo Sun Kwon, Hyo Song Kim, Choong-kun Lee, Hyun Cheol Chung, So Jung Lim, Eunji Jo, Tae Soo Kim, Hyung Soon Park, Sejung Park
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background The aim of this study is to profile the cytokines and immune cells of body fluid from metastatic gastric cancer (mGC), and evaluate the potential role as a prognostic factor and the feasibility as a predictive biomarker or monitoring sourc
Autor:
Milan Vošmik, Radek Spisek, Vladimír Koucký, Kamila Hladíková, Miroslav Hodek, Petr Čelakovský, Hana Vošmiková, Jan Laco, Ales Ryska, Michal Zábrodský, Viktor Chrobok, Marek Grega, Anna Fialová, Kateřina Rozkošová, Jan Bouček
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-16 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Standard treatment of oropharyngeal squamous cell carcinoma (OPSCC) is associated with high morbidity, whereas immunotherapeutic approaches using PD-1:PD-L1 checkpoint blockade only show moderate response rates in OPSCC patients. Therefore
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-6 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Immune checkpoint inhibition has dramatically transformed the treatment of malignant melanoma. With increasing use, their unique spectrum of immune-mediated toxicity has become apparent. Case presentation We describe a case of sequential i
Autor:
Kenneth R. Hess, Siqing Fu, Abdulrazzak Zarifa, Jeffrey E. Lee, Matthew Campbell, Vivek Subbiah, Funda Meric-Bernstam, Nancy D. Perrier, Coya Tapia, Mouhammed Amir Habra, Shubham Pant, Jordi Rodon Ahnert, Camilo Jimenez, David S. Hong, Bettzy Stephen, Russell R. Boraddus, Mingxuan Xu, Aung Naing, Daniel D. Karp
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Adrenocortical carcinoma (ACC) is a rare malignancy without good treatment options. There are limited data about the use of immunotherapy in ACC. We investigated the efficacy and safety of pembrolizumab in patients with metastatic ACC. Met
Autor:
Marco Marchisio, Emma Di Carlo, Carlo Sorrentino, Li-Fan Lu, Matteo Bellone, Paola Lanuti, Zhinan Yin, Stefania Livia Ciummo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Interleukin(IL)-30/IL-27p28 production by Prostate Cancer (PC) Stem-Like Cells (SLCs) has proven, in murine models, to be critical to tumor onset and progression. In PC patients, IL-30 expression by leukocytes infiltrating PC and draining
Autor:
Dörthe Schaue, William H. McBride, Erik Evensen, Percy Lee, Judith D. Goldberg, Xiaochun Li, Neha Dixit, Claire Vanpouille-Box, Silvia C. Formenti, Rachael E. Hawtin, Sandra Demaria
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Journal for immunotherapy of cancer, vol 7, iss 1
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 7, iss 1
Journal for Immunotherapy of Cancer
Background We previously reported the results of a multicentric prospective randomized trial of chemo-refractory metastatic breast cancer patients testing the efficacy of two doses of TGFβ blockade during radiotherapy. Despite a lack of objective re
Autor:
Curtis J. Perry, Christopher R. Zito, Kevan C. Herold, Lucia B. Jilaveanu, Eric Meffre, Noel Turner, Marcus Bosenberg, William Damsky, Jonathan S. Leventhal, Harriet M. Kluger, Mary M. Tomayko
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background PD-1 inhibitors are approved for multiple malignancies and function by stimulating T cells. However, the role of B cells in the anti-tumor activity of these drugs is unknown, as is their activity in patients who have received B cell deplet